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ABSTRACT 
The purpose of this study is to assess how the introduction of cell-free fetal DNA 
(cffDNA) tests on a population of patients with high-risk for aneuploidy from Maternal 
Fetal Medicine of Lehigh Valley Health Network has affected the use of invasive procedure 
in the practice over a period of time. This study included all women determined by specific 
indicators to be at a high-risk for aneuploidy seen in Maternal Fetal Medicine at Lehigh 
Valley Health Network (LVHN) from 01/01/2012 to 12/31/13 who underwent cell-free 
fetal DNA testing. The cffDNA tests performed during the study period included 
MaterniT21 Plus, Verifi Prenatal Test, and Harmony Prenatal Test. A total of 958 patients 
underwent cffDNA testing during this time period. The results were, 922 negative, 28 
positive, 5 non-reportable, 1 unclassified, and two cancelled tests. There was one false 
positive and two false negatives. The use of non-invasive cffDNA testing increased over the 
two-year period while the use of invasive procedures decreased.  
BACKGROUND 
Fetal aneuploidy is an abnormal number of chromosomes in a fetus’s DNA caused by 
missing or extra chromosomes that originate during cell division. An abnormal number of 
chromosomes can result in genetic disorders and birth defects. The three most common 
types of aneuploidy are Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome) 
and Trisomy 13 (Patau syndrome). Each of these forms of aneuploidy result in mental 
retardation, growth abnormalities, heart abnormalities and significantly increased death 
rate, as well as other distinctive features and abnormalities. Screening for fetal aneuploidy 
is important in both low-risk and high-risk pregnant patients. While the risk of aneuploidy 
does increase with different factors such as advanced maternal age (≥35 years old), all 
patients have some degree of risk. Acknowledging the importance of these tests, starting in 
2007 the American College of Obstetricians and Gynecologists (ACOG) has recommended 
that all pregnant women be offered aneuploidy screening and testing, regardless of risk 
factors (1). 
Both invasive and non-invasive tests are available. Invasive tests, such as 
amniocentesis and chorionic villus sampling (CVS), provide the most accurate information 
but, because they are invasive, are associated with a small risk of miscarriage. Non-invasive 
tests are performed on maternal serum (blood), and are therefore not associated with a 
risk of miscarriage. However, these tests are not precise and produce some false positive 
and false negative results. Previously, the only commercially available noninvasive 
screening tests were maternal blood tests that identified levels of maternal serum 
biochemical markers, such as hCG, PAPP-A, Estriol, Inhibin-A, and AFP, and also used a 
number of factors including age and ethnicity to determine a ratio estimating a patient’s 
chance of fetal aneuploidy (2). Studies show the maternal serum tests have an accuracy of 
80-92% for trisomy 21 and 70-85% for trisomy 18, dependent on the type of test. These 
screening tests can only be performed during the first trimester of pregnancy and require 
specific patient demographics to produce an accurate result (2). Although the sensitivity 
and specificity of screening protocols have improved, until recently, definitive diagnosis 
was possible only through the use of invasive procedures.  
In the fall of 2011, a new form of non-invasive aneuploidy tests for the diagnosis of 
fetal trisomy 13, 18, and 21, and sex chromosome abnormalities first became commercially 
available. These tests are referred to as cell-free fetal DNA (cffDNA) or non-invasive 
prenatal testing (NIPT). These tests evaluate fetal genetic material in the maternal 
circulation and can be offered as early as 10 weeks of pregnancy and can be performed at 
any point during pregnancy (3). Several studies have reported sensitivities and specificities 
for the three different aneuploidies approaching 100% (4,5). The commercial use of the 
tests is less than five years in practice and while supported with many studies, it is in need 
of large-scale clinical trials to confirm results and provide more information for both 
provider and patient. With higher accuracy than previous screening tests, and less risk and 
discomfort than invasive testing, the cffDNA tests have the potential to replace invasive 
testing over time. The purpose of this study is to assess how the introduction of cell-free 
fetal DNA tests on a population of patients with high-risk for aneuploidy from Maternal 
Fetal Medicine of Lehigh Valley Health Network has affected the use of invasive procedure 
in the practice over a period of time.   
METHODS 
This is a retrospective cohort study. The inclusion criteria for this study were all 
women determined by specific indicators to be at a high-risk for aneuploidy seen in 
Maternal Fetal Medicine at Lehigh Valley Health Network (LVHN) from 01/01/2012 to 
12/31/13 who underwent cell-free fetal DNA testing. Indicators of “high-risk” included 
advanced maternal age (AMA-maternal age ≥35), abnormal maternal serum screen, 
abnormal ultrasound findings, and/or family/personal history of aneuploidy. The exclusion 
criteria were women at low risk for aneuploidy. 
Women meeting inclusion criteria were identified in a preexisting Maternal Fetal 
Medicine clinical database used to track these women. Tests performed during the study 
period included MaterniT21 Plus (Sequenom CMM), Verifi Prenatal Test (Verinata), and 
Harmony Prenatal Test (Integrated Genetics). Tests were chosen based on insurance 
coverage/cost to patient, availability of kits to perform a given test, perceptions regarding 
turn-around time and specific characteristics of the test. During the study period all three 
tests began to offer testing for sex chromosome abnormalities; additionally MaterniT21 
Plus added information on chromosomes 16 and 22. Results for MaterniT21 Plus were 
reported as “positive”, “negative”, and “non-reportable” for each trisomy. Non-reportable 
results were due to insufficient fetal DNA from maternal serum. Women with non-
reportable results were offered a redraw or an invasive test. Results for Verifi were 
reported as “aneuploidy detected”, “aneuploidy not detected”, “aneuploidy suspected” or 
“unclassifiable”. Aneuploidy suspected referred to results that could not be accurately 
interpreted. Unclassifiable are those found to be in the gray zone or in the overlap between 
what is considered positive and negative for a specific aneuploidy, and a redraw is not 
recommended in this case. Invasive testing was recommended for both “aneuploidy 
suspected” and “unclassifiable” cases. Results for Harmony were reported as “high risk” or 
“low risk” for each trisomy. Medical records were reviewed and data was collected on 
demographics, indication for test, results, whether they had any invasive testing 
performed, and pregnancy outcomes. Neonatal records and maternal postpartum visit 
records were reviewed whenever possible to confirm neonatal outcome and identify false 
positive and/or false negative results. Descriptive statistics were generated using Excel 
2010. Utilization of cffNDNA as compared to invasive testing over time was determined. 
RESULTS 
A total of 958 patients seen underwent cell-free fetal DNA testing during the study 
period. Two patients cancelled the test prior to results returning (one miscarried and one 
terminated the pregnancy for abnormal ultrasound findings – both opted to have full 
karyotype done on the fetal tissue instead), for a final test cohort of 956. Indications for 
testing included advanced maternal age (40%), abnormal ultrasound (30%), abnormal 
serum screen (27%), and personal/family history (3%)  (Figure 1). On initial testing, 13 
were non-reportable (1.4%). Twelve of the thirteen repeated the test – of those, 4 were 
again non-reportable and the other 8 were all negative. No patients were tested a third 
time, per lab policy. 
For the 951 patients with results, there were 28 (2.9%) positive and 1 (0.1%) 
unclassifiable results (Table 1). Most of the positive results were trisomy 21 (21); the 
remainder were trisomy 18 (4), trisomy 16 (1), triple X (1) and monosomy X (1). Of the 
women that were positive, only 9 had invasive testing to confirm the results. All women 
with confirmed aneuploidy on invasive testing opted to terminate the pregnancy (Figure 
2). Table 2 shows the pregnancy outcome of women with a positive result: 19 continued 
the pregnancy and 9 terminated the pregnancy. There was one false positive (monosomy 
X). There were 2 false negatives (trisomy 13 and trisomy 21). Both of the false negatives 
had ultrasound abnormalities.  
The combined sensitivity and specificity of all three tests were calculated for 
trisomy 21 (Table 3). Only women for whom pregnancy outcomes were confirmed by 
karyotype were included in the calculation. There was not enough data to calculate 
sensitivity and specificity for trisomy 18 (only two confirmed outcomes) and trisomy 13 






(zero outcomes). Sensitivity, specificity, positive predictive value, and negative predictive 
value were 94.7%, 100%, 100% and 99.9%. 
Cell-free fetal DNA test utilization increased significantly over time (Figure 3) and 
was associated with a concomitant decrease in the number of invasive tests being 



















Table 1. Results of cell-free fetal DNA 
testing 
Negative 922/956 (96.4%) 
Positive 28/956 (2.9%) 
Non-reportable 5/956 (0.5%) 














































       *For the results that were confirmed by karyotype 
 





      Live birth 
      Miscarriage 
16/19 
3/19 
Termination 9/29 (32.1%) 









Trisomy 21 94.7% 100% 100% 99.9% 
Figure 2. Use of confirmatory invasive tests for women with positive cell-free fetal 
DNA 
*The invasive test had results of a normal karyotype, identifying a false positive cell 

















































































The American College of Obstetricians and Gynecologists recommends that all 
pregnant women be offered aneuploidy screening and testing. Cell-free fetal DNA is the 
newest option for women who opt to undergo screening. First used in our practice in 
January of 2012, this paper serves to describe our experience over the first two years with 
these tests.  
The commercial use of cell-free fetal DNA tests has demonstrated both its 
advantages and disadvantages compared to previous methods of aneuploidy detection, 
invasive and non-invasive.  Compared to other non-invasive fetal aneuploidy screening 
tests like the maternal serum screen cffDNA has much higher detection rates of 97% to 
100%, supported by many studies validating these high values (5-7). Although cffDNA tests 
do have very high detection rates for aneuploidy, they are not a diagnostic test. The cffDNA 
tests do not produce a full karyotype of the fetus, but instead use comprehensive 
comparisons of fetus DNA fragments against controls to determine aneuploidy. Although 
rare, this method allows for the possibility of false positive and false negative results. 
Therefore, the only method available for diagnostic results of fetal aneuploidy is with 
invasive testing. Invasive testing remains the gold standard for determining any fetal 
aneuploidy.  
Cell-free fetal DNA tests also detect sex chromosome aneuploidies. However, the 
detection rates for these aneuploidies ( X, XXX, XXY, and XYY) are lower than those for 
trisomy 13, 18, with a detection rate of 95% (8). Fewer studies of cffDNA detection of sex 
chromosome aneuploidies have been conducted to verify the lab reported detection rates. 
This increases the uncertainty with the sex chromosome aneuploidy results and allows the 
possibility of accuracy sex chromosome detection accuracy to be much lower for cffDNA, as 
compared to the other aneuploidies it detects until more studies are reviewed.  
The study was consistent with one false positive and two false negatives 
demonstrating the highly accurate but not diagnostic nature of the test. The false positive 
detected a sex chromosome aneuploidy, monosomy X, for a woman whose only high-risk 
indication was advanced maternal age at 38 years old. After receiving a positive result from 
cffDNA, she opted to have invasive testing for conformation. Amniocentesis presented a 
normal male karyotype, and she delivered a healthy baby. The detection rate for sex 
aneuploidy in cffDNA is the least accurate of all the aneuploidy detection rates and the 
results found in our study support the need to further study the detection rates of sex 
chromosome aneuploidy.  
The first false negative found in the study did not detect trisomy 21. The patient 
opted to have cffDNA testing due to AMA (37) and an abnormal maternal serum screen. 
The test came back negative and the patient did not follow up with any invasive procedures 
for diagnosis. She gave birth to a baby boy diagnosed with trisomy 21 after delivery and 
confirmed with chromosome analysis of the baby’s blood.  
The second false negative did not detect Trisomy 13. The patient opted to have 
cffDNA due to AMA. The results were negative however, on a regular twenty week growth 
scan, numerous ultrasound abnormalities surfaced. The patient opted to proceed with 
amniocentesis which diagnosed trisomy 13 in the fetus. After definitive results the patient 
decided to terminate the pregnancy.  
Although false positive and false negative results are rare with cffDNA testing, they 
are still very real limitations of this test as seen within our own study. Invasive testing 
should strongly be considered as the next step after receiving positive aneuploidy results.  
From the twenty-eight positive cffDNA test results, only nine patients decided to 
proceed with invasive testing. Most patients opted to continue the pregnancy without any 
further knowledge of the baby’s karyotype and possible birth defects. Many patients seen 
in Maternal Fetal Medicine of LVHN do not want to alter their pregnancy in any way, even 
when faced with a positive test result. The number of patients who opted to have invasive 
testing is surprisingly low, especially since both the physician and the genetic counselor 
recommend invasive testing to the patient. Of the patients who did have invasive testing to 
confirm, eight terminated and one identified a false negative. The other positive patients 
continued their pregnancy to birth or miscarried. Although a patient may refuse invasive 
testing because they are unwilling to alter pregnancy no matter what, there may still be 
advantages to knowing whether a result is a true positive. It is important to identify all 
false positive tests which is done through invasive testing and also it is important to 
prepare for a pregnancy when a fetus is affect with aneuploidy.  
Since the introduction of the cffDNA tests, the amount of invasive procedures has 
decreased, as the use of the cffDNA tests has increased rapidly. The use of cffDNA tests is 
increasing each year because although not diagnostic, they provide patients with a highly 
accurate detection of aneuploidy in pregnancy without the chance of miscarriage or added 
stress of invasive testing. CffDNA testing is becoming the primary indication of aneuploidy 
with invasive testing secondary as a conformation. 
 
CONCLUSION 
Cell-free fetal DNA is a new prenatal aneuploidy screening test being used with 
increasing frequency in high risk obstetrical patients. As utilization of cffDNA is increasing, 
the performance of invasive (diagnostic) procedures is decreasing due to the high detection 
rates reported for cffDNA. Although detection rates are much better than older aneuploidy 
screening tests, cffDNA should be considered a screen, not a diagnostic test, as it does have 
rare false positive and false negative results. It is therefore important to confirm positive 
cffDNA results with an invasive test. The limitations of this study were found to be the 
ability to confirm aneuploidy in baby after patient delivered. Some patients do not proceed 
with genetic testing for children or if they miscarry and therefore pregnancy outcomes 
cannot be truly confirmed for those patients. CffDNA testing is still a new form of screening 
patients and needs large clinical trials to further understand the limitation of this test. 
Future studies should look at test performance in low-risk populations.  
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